79% of healthcare leaders are optimistic about 2025, citing M&A growth and increased cybersecurity investments amid economic uncertainty.
Quiver AI Summary
FTI Consulting's recent survey revealed that 79% of healthcare and life sciences leaders are optimistic about the industry's financial outlook for 2025, marking an 11% increase from the previous year. A significant portion of respondents anticipates higher mergers and acquisitions (M&A) activity and improved capital raising capabilities. Despite this optimism, leaders identified economic uncertainty, cybersecurity incidents, and political uncertainty as key challenges. As leaders prepare for a potential second Trump administration, they expect regulatory changes and focus on market-driven solutions. Notably, there is an increased emphasis on cybersecurity preparedness, with many companies implementing crisis communication plans and simulations to better address emerging threats.
Potential Positives
- 79% of industry leaders express increased optimism about the healthcare and life sciences sector, indicating a positive trend in confidence and financial outlook.
- 66% of leaders anticipate higher mergers and acquisitions (M&A) activity in 2025, suggesting a more dynamic market that could benefit FTI Consulting's advisory services.
- 53% of surveyed executives have participated in crisis simulations, highlighting growing recognition of the importance of crisis preparedness, which aligns with FTI Consulting's expertise in risk mitigation and reputation management.
Potential Negatives
- The press release highlights significant concerns about economic uncertainty (38%), political uncertainty (22%), and cybersecurity incidents (23%), indicating a lack of stability in the industry that could impact FTI Consulting's business environment.
- Political uncertainty rose in prominence, particularly concerning the potential implications of a second Trump administration, which may create unpredictability in regulatory landscapes affecting the healthcare and life sciences sectors.
- The mention of increasing cybersecurity incidents suggests that FTI Consulting and its clients face heightened reputational and operational risks, which may affect their overall trustworthiness and effectiveness in their services.
FAQ
What findings were reported in the 2025 Healthcare & Life Sciences Outlook?
The report reveals that 79% of industry leaders feel optimistic about the financial outlook, an increase from last year.
What key challenges do industry leaders face?
Industry leaders cited economic uncertainty, cybersecurity incidents, and political uncertainty as the main challenges affecting their businesses.
How are companies preparing for cybersecurity incidents?
Sixty-eight percent of respondents have a crisis communications plan in place, and 53% have participated in crisis simulations.
What areas are expected to see increased M&A activity?
Expected areas of M&A activity include obesity treatments, immuno-oncology, gene editing, and AI-powered drug discovery.
How might a potential Trump administration impact the healthcare industry?
Leaders expect a focus on reducing federal regulations and promoting market-based solutions that could benefit the business environment.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$FCN Insider Trading Activity
$FCN insiders have traded $FCN stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $FCN stock by insiders over the last 6 months:
- GERARD E HOLTHAUS sold 1,329 shares.
- HOLLY PAUL (Chief Human Resources Officer) has traded it 2 times. They made 0 purchases and 2 sales, selling 4,078 shares.
- MARK S. BARTLETT has traded it 2 times. They made 0 purchases and 2 sales, selling 2,000 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$FCN Hedge Fund Activity
We have seen 210 institutional investors add shares of $FCN stock to their portfolio, and 191 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GREENVALE CAPITAL LLP removed 360,000 shares (-100.0%) from their portfolio in Q3 2024
- BLACKROCK, INC. added 312,749 shares (+10.1%) to their portfolio in Q3 2024
- FIL LTD removed 310,600 shares (-50.0%) from their portfolio in Q3 2024
- PRICE T ROWE ASSOCIATES INC /MD/ added 132,655 shares (+9.6%) to their portfolio in Q3 2024
- VICTORY CAPITAL MANAGEMENT INC removed 132,136 shares (-6.4%) from their portfolio in Q3 2024
- MAWER INVESTMENT MANAGEMENT LTD. added 123,177 shares (+3.2%) to their portfolio in Q3 2024
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 114,062 shares (+26.4%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
79% of Industry Leaders Feel Optimistic About Industry’s Potential
Economic Uncertainty, Cybersecurity Incidents and Political Uncertainty Seen as Key Challenges
Industry Increasingly Investing in Cybersecurity Preparedness
WASHINGTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced the results of its U.S. Healthcare & Life Sciences Industry Outlook 2025 , which found that after years of tempered expectations, 79% of leaders are increasingly optimistic about the industry and its financial outlook, up 11% from last year’s survey .
According to the survey, 66% of leaders expect higher M&A activity in 2025 and 4 in 10 respondents expect a greater ability to raise capital, up 10% from last year. The increasing confidence in dealmaking and fundraising is a strong indication of the industry’s renewed optimism going into the coming year.
“After years of speculation and tempered optimism, M&A activity is expected to increase in 2025, as companies predominantly look to acquire viable, late-stage assets in order to grow their pipeline and accomplish their business objectives,” said Robert Stanislaro , a Senior Managing Director and Head of the Healthcare & Life Sciences’ Corporate Reputation offering within the Strategic Communications segment at FTI Consulting. “Particular areas of investment include the rise of obesity treatments, an increased focus in immuno-oncology, gene editing and AI-powered drug discovery. The growing optimism amongst industry leaders and key stakeholders opens up the opportunity for companies to position themselves as innovators in the field and rise above the crowded marketplace.”
Looking at potential risks and challenges, those surveyed cited economic uncertainty (38%) as the biggest liability facing the industry, followed by cybersecurity (23%) and political uncertainty (22%). Notably, political uncertainty rose in prominence this year as leaders reflected on the potential implications of the U.S. presidential election.
While the survey was conducted prior to the results of the U.S. presidential election, the findings provide insights into how the industry may be preparing for a second Trump administration. In October 2024, nearly 6 in 10 respondents stated that a potential Trump administration would have a positive impact on their business.
“As the industry prepares for a second Trump administration, leaders should expect to see a focus on reducing federal regulations, promoting market-based solutions and competition through a more favorable deal-making environment, addressing the cost of prescription drugs, and decreasing federal involvement in health coverage,” said Lauren Crawford Shaver , Americas Head of Healthcare & Life Sciences within FTI Consulting’s Strategic Communications segment. “While some changes could be implemented via executive orders, other major reforms would require congressional support and face substantial political hurdles. In light of this, industry leaders need to not only monitor but also grow their political relationships at the local, state and federal level.”
Cybersecurity incidents have become increasingly prevalent across the industry. With that, executives are becoming more familiar with the reputational and operational challenges these situations pose and are preparing accordingly. Sixty-eight percent of respondents said they have a crisis communications plan in place and 53% have participated in a crisis simulation, up 13% and 37% from 2024, respectively.
The full survey report is available here .
About the Survey
This research was conducted online by FTI Consulting’s Strategic Communications segment between September 24 – October 9, 2024, with 250 decision-makers in corporate communications, investor relations, public affairs, business development and marketing for healthcare and life sciences companies in the United States. Forty-three percent of respondents represent large companies (with more than 250 employees), and roughly one third (35%) represent publicly listed companies with a weighted average $5 billion market cap.
About FTI Consulting
FTI Consulting, Inc. is a global business advisory firm dedicated to helping organizations manage change, mitigate risk and resolve disputes: financial, legal, operational, political & regulatory, reputational and transactional. With more than 8,300 employees located in 34 countries and territories, FTI Consulting professionals work closely with clients to anticipate, illuminate and overcome complex business challenges and make the most of opportunities. The Company generated $3.49 billion in revenues during fiscal year 2023. In certain jurisdictions, FTI Consulting’s services are provided through distinct legal entities that are separately capitalized and independently managed. More information can be found at
www.fticonsulting.com
.
FTI Consulting, Inc.
555 12
th
Street NW
Washington, DC 20004
+1.202.312.9100
Investor Contact:
Mollie Hawkes
+1.617.747.1791
[email protected]
Media Contact:
Matthew Bashalany
+1.617.897.1545
[email protected]